Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone - PubMed (original) (raw)
Clinical Trial
. 2002 Jul 1;100(1):48-51.
doi: 10.1182/blood.v100.1.48.
Affiliations
- PMID: 12070007
- DOI: 10.1182/blood.v100.1.48
Free article
Clinical Trial
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone
Sibel Koc et al. Blood. 2002.
Free article
Abstract
Results of previous studies have suggested that transplantation-related mortality among patients with chronic graft-versus-host disease (GVHD) may be reduced by combined treatment with cyclosporine (CSP) and prednisone rather than by prednisone alone. In a randomized trial, we assessed the efficacy of cyclosporine plus prednisone versus prednisone alone as initial therapy for chronic GHVD among patients whose platelet counts were higher than 100,000/microL. Prednisone was administered initially at a dose of 1.0 mg/kg per day orally, followed by a prolonged taper, and cyclosporine was administered at 6 mg/kg orally twice daily every other day. The cumulative incidence of transplantation-related mortality at 5 years from enrollment was 17% (95% CI, 0.11-0.23) in the CSP plus prednisone arm and 13% (95% CI, 0.08-0.19) in the prednisone arm. The hazards of transplantation-related mortality, overall mortality, recurrent malignancy, secondary therapy, and discontinuation of all immunosuppressive therapy were not significantly different between the 2 arms, but survival without recurrent malignancy was lower in the 2-drug arm (P =.03). Avascular necrosis developed in 18 (13%) of the 142 patients in the CSP plus prednisone arm and in 32 (22%) of the 145 patients in the prednisone arm (P =.04). Treatment with CSP plus prednisone may reduce the risk for steroid-related toxicity, but results of the current study do not substantiate the hypothesis that the administration of CSP reduces transplantation-related mortality among patients with chronic GVHD.
Similar articles
- Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. Sandmaier BM, et al. Lancet Haematol. 2019 Aug;6(8):e409-e418. doi: 10.1016/S2352-3026(19)30088-2. Epub 2019 Jun 24. Lancet Haematol. 2019. PMID: 31248843 Free PMC article. Clinical Trial. - Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.
Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR, Chauncey TR, Doney K, Flowers M, Martin P, Nash R, Schoch G, Sullivan KM, Witherspoon RP, Storb R. Deeg HJ, et al. Blood. 1997 May 15;89(10):3880-7. Blood. 1997. PMID: 9160697 Clinical Trial. - Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR. Kumar S, et al. Bone Marrow Transplant. 2001 Jun;27(11):1133-40. doi: 10.1038/sj.bmt.1703053. Bone Marrow Transplant. 2001. PMID: 11551023 - Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, Amylon MD, Tierney DK, O'Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Bluzme KG. Chao NJ, et al. Biol Blood Marrow Transplant. 2000;6(3):254-61. doi: 10.1016/s1083-8791(00)70007-3. Biol Blood Marrow Transplant. 2000. PMID: 10871150 Clinical Trial. - Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, Miller WJ, Weisdorf DF. Arora M, et al. Biol Blood Marrow Transplant. 2001;7(5):265-73. doi: 10.1053/bbmt.2001.v7.pm11400948. Biol Blood Marrow Transplant. 2001. PMID: 11400948 Clinical Trial.
Cited by
- Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD.
Olivieri A, Mancini G. Olivieri A, et al. Cells. 2024 Sep 11;13(18):1524. doi: 10.3390/cells13181524. Cells. 2024. PMID: 39329708 Free PMC article. Review. - Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD.
Wang Y, Ullah MA, Waltner OG, Bhise SS, Ensbey KS, Schmidt CR, Legg SR, Sekiguchi T, Nelson EL, Kuns RD, Nemychenkov NS, Atilla E, Yeh AC, Takahashi S, Boiko JR, Varelias A, Blazar BR, Koyama M, Minnie SA, Clouston AD, Furlan SN, Zhang P, Hill GR. Wang Y, et al. J Clin Invest. 2024 Jun 3;134(11):e170125. doi: 10.1172/JCI170125. J Clin Invest. 2024. PMID: 38828727 Free PMC article. - Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study.
Ayuk F, Wagner-Drouet EM, Wolff D, von Huenerbein N, von Pein UM, Klyuchnikov E, von Harsdorf S, Koenecke C, Sayer H, Kröger N. Ayuk F, et al. Bone Marrow Transplant. 2024 Aug;59(8):1092-1096. doi: 10.1038/s41409-024-02289-0. Epub 2024 May 2. Bone Marrow Transplant. 2024. PMID: 38698080 Free PMC article. Clinical Trial. - Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.
Kim DDH, Popradi G, Lepic K, Paulson K, Allan D, Nampoothiri RV, Lachance S, Deotare U, White J, Elemary M, Jamani K, Fraga C, Lemieux C, Novitzky-Basso I, Law AD, Kumar R, Walker I, Schultz KR; CTTC Chronic GVHD Guideline Working Group. Kim DDH, et al. Curr Oncol. 2024 Mar 8;31(3):1426-1444. doi: 10.3390/curroncol31030108. Curr Oncol. 2024. PMID: 38534941 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical